Table 3.
Input Data for discretised HAQ score and continuous ACR: Number of patients N; number of HAQ20 and HAQ50 responders; continuous ACR response ACRcont; + indicates additional treatment with MTX
| Trial | Arm | N | HAQ20 | HAQ50 | ACRcont (SD) |
|---|---|---|---|---|---|
| Weinblatt et al. [31] |
P+ |
62 |
30 |
12 |
0.08 (0.22) |
| |
Ada+ |
69 |
45 |
24 |
0.35 (0.20) |
| |
Ada+ |
67 |
47 |
26 |
0.46 (0.22) |
| |
Ada+ |
73 |
52 |
26 |
0.42 (0.21) |
| Keystone et al. [32] |
P+ |
200 |
95 |
32 |
0.13 (0.22) |
| |
Ada+ |
212 |
141 |
81 |
0.42 (0.21) |
| |
Ada+ |
207 |
154 |
82 |
0.41 (0.21) |
| Van de Putte et al. [33] |
P |
110 |
29 |
4 |
0.09 (0.20) |
| |
Ada |
112 |
47 |
16 |
0.31 (0.19) |
| |
Ada |
106 |
60 |
19 |
0.30 (0.19) |
| |
Ada |
103 |
57 |
20 |
0.38 (0.22) |
| |
Ada |
113 |
60 |
21 |
0.33 (0.20) |
| Miyasaka [34] |
P |
87 |
23 |
8 |
0.07 (0.17) |
| |
Ada |
87 |
37 |
10 |
0.28 (0.19) |
| |
Ada |
91 |
39 |
16 |
0.33 (0.20) |
| |
Ada |
87 |
48 |
18 |
0.37 (0.21) |
| Kim et al. [35] |
P+ |
63 |
28 |
10 |
0.18 (0.27) |
| |
Ada+ |
65 |
43 |
24 |
0.42 (0.22) |
| Maini et al. [36] |
P+ |
88 |
40 |
9 |
0.09 (0.19) |
| |
Inf+ |
86 |
40 |
12 |
0.35 (0.19) |
| |
Inf+ |
86 |
54 |
19 |
0.36 (0.20) |
| |
Inf+ |
87 |
52 |
23 |
0.38 (0.21) |
| |
Inf+ |
81 |
48 |
20 |
0.37 (0.19) |
| Westhoven et al. [37] |
P+ |
363 |
- |
- |
0.12 (0.23) |
| |
Inf+ |
360 |
- |
- |
0.37 (0.20) |
| |
Inf+ |
361 |
- |
- |
0.38 (0.21) |
| Zhang et al. [38] |
P+ |
86 |
52 |
28 |
0.27 (0.31) |
| |
Inf+ |
87 |
61 |
39 |
0.46 (0.20) |
| Schiff et al. [39] |
P+ |
110 |
- |
- |
0.22 (0.29) |
| |
Inf+ |
165 |
- |
- |
0.41 (0.22) |
| Moreland et al. [40] |
P |
80 |
25 |
8 |
0.06 (0.16) |
| |
Eta |
76 |
47 |
26 |
0.34 (0.19) |
| |
Eta |
78 |
53 |
31 |
0.40 (0.21) |
| Weinblatt et al. [41] |
P+ |
30 |
16 |
8 |
0.10 (0.17) |
| |
Eta+ |
59 |
45 |
29 |
0.43 (0.19) |
| Keystone et al. [42] |
P+ |
133 |
49 |
13 |
0.14 (0.25) |
| |
Gol |
133 |
56 |
29 |
0.30 (0.20) |
| |
Gol+ |
89 |
51 |
24 |
0.40 (0.22) |
| |
Gol+ |
89 |
60 |
31 |
0.39 (0.21) |
| Kay et al. [43] |
P+ |
35 |
- |
- |
0.14 (0.20) |
| |
Gol+ |
35 |
- |
- |
0.39 (0.20) |
| |
Gol+ |
34 |
- |
- |
0.38 (0.21) |
| Keystone et al. [44] |
P+ |
199 |
83 |
35 |
0.07 (0.20) |
| |
Cert+ |
393 |
263 |
146 |
0.40 (0.22) |
| |
Cert+ |
390 |
249 |
137 |
0.41 (0.22) |
| Smolen et al. [45] |
P+ |
127 |
46 |
10 |
0.04 (0.14) |
| |
Cert+ |
246 |
163 |
66 |
0.38 (0.21) |
| |
Cert+ |
246 |
155 |
67 |
0.38 (0.20) |
| Fleischmann et al. [46] |
P |
109 |
19 |
2 |
0.04 (0.14) |
| Cert | 111 | 60 | 34 | 0.33 (0.19) |
Ada=adalimumab; Inf=infliximab; Eta=etanercept; Gol=golimumab, Cert=certolizumab, P=placebo.